Actavis Claims Cancer Drug Patents Are Invalid
Actavis Group hf has struck back against a lawsuit filed by Sanofi-Aventis U.S. LLC alleging infringement of a patent for Eloxatin, saying it is not violating patents for the colon cancer...To view the full article, register now.
Already a subscriber? Click here to view full article